UPMC Cancer Centers
Welcome,         Profile    Billing    Logout  
 91 Trials 
57 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kirkwood, John M
ATLAS-IT-05, NCT04796194: Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma

Active, not recruiting
2
20
Europe, US
LTX-315 in combination with pembrolizumab
Lytix Biopharma AS, Laboratory Corporation of America, OWL
Advanced Melanoma
12/24
12/24
NCT03743766: Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Completed
2
42
US
Relatlimab, BMS-986016, Nivolumab, BMS-936558, Relatlimab + Nivolumab, BMS-986016 and BMS-936558
John Kirkwood, Bristol-Myers Squibb
Melanoma
07/24
07/24
NCT02535078 / 2015-002971-12: Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Checkmark OS data from trial in combination with durvalumab and tremelimumab for cutaneous melanoma
Jun 2022 - Jun 2022: OS data from trial in combination with durvalumab and tremelimumab for cutaneous melanoma
Withdrawn
1/2
113
US
Tebentafusp (IMCgp100)
Immunocore Ltd, AstraZeneca
Malignant Melanoma
06/23
09/23
NCT04370587: A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Recruiting
1/2
64
US, RoW
T3011, T3011 + pembrolizumab
ImmVira Pharma Co. Ltd
Solid Tumor, Melanoma, HNSCC, Sarcoma, Squamous Cell Carcinoma, NSCLC
10/23
10/25
NCT04157517: A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Terminated
1/2
45
US, RoW
Modakafusp Alfa, TAK-573, Pembrolizumab
Takeda
Neoplasms, Melanoma
12/23
12/23
NCT04688658: Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

Active, not recruiting
1/2
13
US
Nivolumab, Opdivo, AG013736, Duvelisib, Copiktra
John Kirkwood, Secura Bio, Inc., Bristol-Myers Squibb
Unresectable Melanoma
02/24
12/28
Bahary, Nathan
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
NCT05766748: Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Recruiting
1/2
30
US
Azeliragon, TTP488
Cantex Pharmaceuticals
Metastatic Pancreatic Cancer
02/25
05/25
Sun, Weijing
NCT03488667: Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Active, not recruiting
2
40
US
Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab
University of Kansas Medical Center, Merck Sharp & Dohme LLC
Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
04/24
04/25
daNIS-3, NCT04952753 / 2021-000553-40: Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

Completed
2
204
Europe, Canada, Japan, US, RoW
NIS793, Bevacizumab, Modified FOLFOX6, 5FU+Leucovorin+Oxaliplatin, FOLFIRI, 5FU+Leucovorin+Irinotecan, Tislelizumab, VDT482
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Colorectal Cancer
01/25
01/25
NCT04169347: FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Active, not recruiting
2
27
US
Oxaliplatin, Irinotecan, Leucovorin, Panitumumab
Criterium, Inc., Amgen
Colorectal Cancer Metastatic
12/24
01/25
Tarhini, Ahmad
NCT04526730: Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

Active, not recruiting
2
17
US
Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System, Electroporation
H. Lee Moffitt Cancer Center and Research Institute, OncoSec Medical Incorporated
Melanoma
06/28
06/28
NCT04869137: Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Active, not recruiting
2
26
US
Lenvatinib Oral Product, LENVIMA, Pembrolizumab, Keytruda
H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC
Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin
09/25
09/26
NCT06295159: Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Recruiting
2
90
US
Nivolumab, Opdivo, Nivolumab + Relatlimab, Opdualag, Ipilimumab, Yervoy
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
07/27
07/27
NCT04562129: IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Recruiting
2
29
US
Interleukin-2, Aldesleukin, Ipilimumab, Nivolumab
H. Lee Moffitt Cancer Center and Research Institute, Clinigen, Inc.
Melanoma Stage III, Melanoma Stage IV, Inoperable Disease
08/25
11/29
NCT05170334: Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

Recruiting
2
32
US
Binimetinib, Mektovi, ARRY-162, Belinostat, Beleodaq
H. Lee Moffitt Cancer Center and Research Institute, Pfizer, Acrotech Biopharma Inc.
Metastatic Uveal Melanoma
09/25
12/25
NCT05524935: Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Recruiting
2
37
US
Pembrolizumab, Keytruda, Olaparib, AZD2281, KU-0059736, Lynparza
H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC
Uveal Melanoma, Ocular Melanoma
07/26
07/26
NCT06121180: Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Recruiting
2
32
US
ZIV-Aflibercept, Zaltrap, Eylea, Cemiplimab, Libtayo
H. Lee Moffitt Cancer Center and Research Institute, Genzyme, a Sanofi Company, Regeneron Pharmaceuticals
Metastatic Uveal Melanoma
10/30
10/30
KEYNOTE-E64, NCT04787042: Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Recruiting
1/2
316
US
ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], GAZYVA, pembrolizumab, KEYTRUDA®
Simcha IL-18, Inc., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
06/25
12/25
DRAGON, NCT04291079: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
112
US, RoW
SRK-181, anti-PD-(L)1 antibody therapy
Scholar Rock, Inc.
Cancer
12/24
12/24
NCT04975152: Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Recruiting
1
30
US
Cemiplimab-Rwlc, Libtayo
H. Lee Moffitt Cancer Center and Research Institute, Regeneron Pharmaceuticals, Sanofi-Synthelabo
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
06/27
06/27
NCT03114319: Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Active, not recruiting
1
227
Europe, Canada, Japan, US, RoW
TNO155, TNO155 in combination with EGF816 (nazartinib)
Novartis Pharmaceuticals
Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma
05/25
05/25
C-1100-01, NCT04121676: Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

Completed
1
91
US
AGEN2373, Anti-CD137, Botensilimab, AGEN1181, Anti-CTLA-4
Agenus Inc.
Advanced Cancer
02/24
11/24
NCT04242147: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors

Terminated
1
45
US
KD033 (SAR445710)
Kadmon, a Sanofi Company
Solid Tumor
12/23
12/23
NCT04741997: Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Recruiting
1
50
US
Encorafenib Pill, Binimetinib Pill, Nivolumab
H. Lee Moffitt Cancer Center and Research Institute, Pfizer
Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
01/25
01/26
NCT05651828: Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

Recruiting
1
34
US
Vismodegib 150 MG Oral Capsule, Erivedge
H. Lee Moffitt Cancer Center and Research Institute, Genentech, Inc.
Advanced Basal Cell Carcinoma
12/28
12/29
Ferris, Robert L
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
NCT03715946: Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

Completed
2
40
US
Nivolumab Injection, BMS-936558, Radiotherapy (RT)
Robert L. Ferris, MD, PhD, Bristol-Myers Squibb
Carcinoma, Squamous Cell of Head and Neck, Oropharynx Squamous Cell Carcinoma
03/23
03/24
CA224-056, NCT04080804: Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Recruiting
2
80
US
Nivolumab, anti-PD-1 antibody, OPDIVO®, Relatlimab, anti-LAG3 antibody, BMS-986016, Ipilimumab, anti-CTLA4 antibody, Yervoy ®
Dan Zandberg, Bristol-Myers Squibb
Head and Neck Squamous Cell Carcinoma (HNSCC)
05/26
09/26
Wegner, Rodney E
S22-11168, NCT06359379: Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Recruiting
2
54
US
Ropidoxuridine, 5-iodo-2-pyrimidinone-2'-deoxyribose
Shuttle Pharmaceuticals, Inc.
Glioblastoma, IDH-wildtype
08/26
02/27
NCT05341739: A Phase II Study of Pre-Op SRS Followed by Surgical Resection for Brain Metastases

Recruiting
N/A
20
US
Pre-operative Stereotactic Radiosurgery
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), Elekta Limited
Brain Metastases, Adult
07/24
12/24
Wang, Hong
HER2CLIMB-02, NCT03975647 / 2019-005017-39: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Jan 2024 - Dec 2024: From HER2CLIMB-02 trial for breast cancer
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of HER2CLIMB-02 trial in combination with Kadcyla for breast cancer
Active, not recruiting
3
466
Europe, Canada, Japan, US, RoW
tucatinib, ONT-380, placebo, T-DM1, Kadcyla
Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc
HER2-positive Breast Cancer
06/23
10/27
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
SURPASS-CN-INS, NCT05691712: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

Completed
3
257
RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
07/24
07/24
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
NCT05520177: A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss

Recruiting
3
350
RoW
601 1.25mg, 601, ranibizumab 0.5mg, Lucentis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Branch Retinal Vein Occlusion
12/25
12/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT04398940: A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer

Recruiting
2
71
RoW
TQ-B3139
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
01/22
10/22
NCT06212297: Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

Recruiting
1/2
9
RoW
LX101
Innostellar Biotherapeutics Co.,Ltd
Inherited Retinal Dystrophy
09/24
03/29
NCT04458389: A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas

Recruiting
1/2
268
RoW
TY101
Tayu Huaxia Biotech Medical Group Co., Ltd.
Locally Advanced /Metastatic Solid Tumors, Relapsed or Refractory Lymphomas
06/24
07/25
NCT05715333: Study of CM326 Injection in Healthy Subjects

Completed
1
46
RoW
CM326, Placebo
Keymed Biosciences Co.Ltd
Healthy
10/23
10/23
NCT06432738: ZL-82 Double-blind Clinical Trial

Recruiting
1
40
RoW
ZL-82, 600mg ZL-82, 50mg ZL-82, 100mg ZL-82, 200mg ZL-82, ZL-82 placebo, 600mg ZL-82 placebo, 50mg ZL-82 placebo, 100mg ZL-82 placebo, 200mg ZL-82 placebo
Chengdu Zenitar Biomedical Technology Co., Ltd
Healthy Person
08/24
12/24
NCT05702450: Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310

Completed
1
240
RoW
CM310
Keymed Biosciences Co.Ltd
Healthy
07/23
07/23
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System

Not yet recruiting
N/A
2150
RoW
Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy
Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Heart Disease
01/26
01/28
Clump, David A
MIT-001, NCT04651634: for Prevention of CCRT-Induced OM in HNSCC Patients

Recruiting
2
60
US, RoW
MIT-001 plus CCRT
MitoImmune Therapeutics
Head and Neck Squamous Cell Carcinoma, Oral Mucositis
04/24
12/24
KEYSTROKE, NCT03546582: SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Recruiting
2
102
Canada, US
Pembrolizumab, Keytruda, Stereotactic Body Radiation Therapy (SBRT), SBRT
RTOG Foundation, Inc., Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma (HNSCC)
07/27
07/29
PREDICT, NCT03448926: The Registry:

Recruiting
N/A
3000
US
Treatment Recommendation Surveys, 7-gene biosignature
PreludeDx, University of South Florida
DCIS
12/25
12/35
Tawbi, Hussein A
NCT06594991: A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

Recruiting
2
88
US
Fianlimab, Cemiplimab, Ipilimumab
Memorial Sloan Kettering Cancer Center, Regeneron Pharmaceuticals
Advanced Melanoma
09/27
09/27
NCT02816021: Study of Oral Azacitidine (CC-486) in Combination with Pembrolizumab (MK-3475) in Patients with Metastatic Melanoma

Active, not recruiting
2
24
US
Azacitidine, 5-azacytidine, 5-aza, Vidaza, 5-AZC, Ladakamycin, NSC-102816, Azacytidine, Pembrolizumab, Keytruda, MK-3475, SCH-900475
M.D. Anderson Cancer Center, Merck Sharp & Dohme LLC, Celgene
Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma
02/25
02/26
NCT03131908: Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

Active, not recruiting
1/2
27
US
GSK2636771, Pembrolizumab, Keytruda, MK-3475, SCH-900475
M.D. Anderson Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH), Merck Sharp & Dohme LLC, GlaxoSmithKline
Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma
12/25
12/25
NCT01366144: Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Active, not recruiting
1
94
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pharmacological Study, Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI), Abbott
Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma, Liver Failure, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Testicular Neoplasm, Melanoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Renal Failure, Unresectable Malignant Neoplasm, Urothelial Carcinoma
11/17
03/25
Syntrix-SX682-Melanoma-101, NCT03161431: SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Checkmark Anticipated initial clinical data in combination with SX-682 for metastatic melanoma
Oct 2020 - Oct 2020: Anticipated initial clinical data in combination with SX-682 for metastatic melanoma
Recruiting
1
77
US
SX-682, Pembrolizumab, KEYTRUDA
Syntrix Biosystems, Inc., Massachusetts General Hospital, National Cancer Institute (NCI), Dana-Farber Cancer Institute, Mayo Clinic, University of Rochester, M.D. Anderson Cancer Center, University of Miami
Melanoma Stage III, Melanoma Stage IV
06/25
06/26
CA101-001, NCT04423029 / 2021-000038-33: A Study of DF6002 Alone and in Combination With Nivolumab

Recruiting
1
438
Europe, US, RoW
DF6002, Nivolumab, Opdivo
Dragonfly Therapeutics
Solid Tumors
01/27
11/27
CA209-6D9, NCT05704933: Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Active, not recruiting
1
16
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab + Relatlimab, Opdualag, Standard of Care Craniotomy
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Metastatic Melanoma, Metastasis to Brain
06/24
06/25
Pope, Nicole
No trials found
Maguire, Mollie
No trials found
Resick, Judi
No trials found

Download Options